Dementia and Alzheimer Disease

The director of the Center for Brain Health at Miami University Miller School of Medicine discussed how much influence people have on lowering their Alzheimer disease risk.

Michael Weiner, MD, professor of radiology and biomedical imaging, medicine, psychiatry, and neurology at the University of California–San Francisco, discussed the findings of a systematic review aimed at evaluating models that predict dichotomous Aß.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 20, 2021.

The chief medical officer of Wave Life Sciences spoke on the FOCUS-C9 study and the potential of WVE-004 to generate positive outcomes for patients.

Yanhong Shi, PhD, director, stem cell biology research, City of Hope National Medical Center, discussed the potential of a new brain organoid model, which was developed to study sporadic Alzheimer disease.

The potential of a new investigational treatment, WVE-004, was discussed by the chief medical officer of Wave Life Sciences, the company that developed the molecule for C9-ALS and C9-FTD.

The global head of Neurodegeneration at Roche/Genentech shared insight into the development of the company’s NeuroToolKit and its use in its Alzheimer disease research.

The director of stem cell biology research at City of Hope spoke on the newly developed brain organoid, which has the potential to help investigators identify pathological mechanisms of Alzheimer disease.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine provided context on greenhouse spaces and their preventive benefits in Alzheimer disease.

Microvesicles excellently discriminated between the relapsing-remitting MS and control groups and between radiologically isolated syndrome and unspecific brain lesions.

Yanhong Shi, PhD, director of stem cell biology research at City of Hope, discussed the new brain organoid, which was derived from human induced pluripotent stem cell technology to better study and understand sporadic Alzheimer disease.

The director of the division of stem cell biology research at City of Hope discussed the potential of the model to study the mechanistic causes of Alzheimer disease and to test dementia drugs currently in development.

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the clinical significance of his findings on neighborhood tree canopy and brain health.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.

The VA health system, which provides medical benefits to more than 9 million veterans, rebuked the drug due to lack of demonstrated efficacy and safety concerns.

The chief medical officer of Wave Life Sciences, Michael Panzara, MD, MPH, discussed the potential of an investigational new treatment, WVE-004, for patients with C9orf72-associated ALS and FTD.

Michael Panzara, MD, MPH, chief medical officer of Wave Life Sciences, spoke on the FOCUS-C9 study, which recently began dosing of an investigational treatment, WVE-004, for patients with ALS and FTD.

Following the commencement of a study exploring WVE-004, an investigational treatment for C9-ALS and C9-FTD, the director of the Sean M. Healey & AMG Center for ALS discussed the clinical implications and the treatment’s potential.

The professor of health science at the Medical University of South Carolina discussed robust results from the phase 3 ADMET 2 study evaluating methylphenidate to treat apathy in Alzheimer disease.

The director of the Sean M. Healey & AMG Center for ALS outlined the trial, which will evaluate ideal dose level and frequency of the investigational treatment for patients with C9-ALS and C9-FTD.

The executive director of Banner Alzheimer’s Institute discussed the approval of aducanumab and the potential to address unmet needs and gaps in care for patients with Alzheimer disease.

Developed by Wave Life Sciences, the trial of the investigational treatment, WVE-004, seeks to identify ideal dose level and frequency in patients with C9orf72-associated amyotrophic lateral sclerosis and FTD.

The approval of aducanumab and other advancements in Alzheimer disease diagnosis remain at the forefront of discussion; Eric Reiman, MD, spoke on the state of diagnosis and those ongoing conversations.

Here's what is coming soon to NeurologyLive.

Mike Detke, MD, PhD, chief medical officer, Cortexyme, provided context on atuzaginstat’s high ceiling in Alzheimer disease, its regulatory path, and its unique dental substudy.

The executive director of Banner Alzheimer’s Institute discussed the future of blood tests as a biomarker that may help in addressing current challenges, including drug development.

The professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at UNLV spoke to the recently published HARMONY phase 3 study data.

Neurology News Network for the week ending August 7, 2021.